Verfügbarkeit: Infliximab :: THWS Bibkatalog

Infliximab: pharmacology, uses and limitations

Gespeichert in:

Bibliographische Detailangaben
Format:	Elektronisch E-Book
Sprache:	English
Veröffentlicht:	New York Nova Science Publishers ©2012
Schriftenreihe:	Immunology and immune system disorders Pharmacology-research, safety testing, and regulation series
Schlagworte:	Autoimmune Diseases / drug therapy Anti-inflammatory agents Infliximab / Therapeutic use Infliximab MEDICAL / Immunology Autoimmune diseases / Chemotherapy Medizin Autoimmune diseases > Chemotherapy
Online-Zugang:	FAW01 FAW02
Beschreibung:	"Nova biomedical." Includes bibliographical references and index ""INFLIXIMAB PHARMACOLOGY, USES AND LIMITATIONS ""; ""INFLIXIMAB PHARMACOLOGY, USES AND LIMITATIONS ""; ""Contents ""; ""Preface ""; ""The Risk of Infection in Patients Treated with Infliximab ""; ""Abstract ""; ""1. Definition and Functions of Tumour Necrosis Factor ""; ""2. Anti-TNF Mechanism of Action: Infliximab ""; ""3. Risk of Infections in the Use of Infliximab: Evidence""; ""4. Risk of Infection from the Use of Anti-TNF (Inflximab): Mechanisms Involved""; ""5. Other Risk Factors for Infection in Patients Treated with Infliximab ""; ""6. Infections ""; ""Bacterial Infections"" ""Listeria """"Tuberculosis ""; ""Virus ""; ""Fungal Infections ""; ""Histoplasmosis ""; ""Coccidioidomycosis ""; ""Cryptococcosis ""; ""Aspergillosis ""; ""Candidiasis""; ""Pneumocystosis ""; ""7. Special Situations""; ""Perisurgical Infections ""; ""Hepatitis B Virus Infection ""; ""Hepatitis C Virus Infection ""; ""HIV Infection ""; ""Vaccines ""; ""Conclusions ""; ""References ""; ""Infliximab in Inflammatory Bowel Disease ""; ""Abstract ""; ""Pharmacology""; ""Uses ""; ""Inflammatory Crohnâ€?s Disease ""; ""Fistulizing Crohnâ€?s Disease ""; ""Ulcerative Colitis""; ""Mucosal Healing "" ""Pouchitis""""Extraintestinal Manifestations ""; ""Limitations ""; ""Predictors of Response to Infliximab ""; ""Infections ""; ""Malignancies and Lymphoma ""; ""Cutaneous, Neurological and Liver Manifestations ""; ""Congestive Heart Failure ""; ""Pregnancy ""; ""References ""; ""Infliximab: Up-to-Date on Indications and Warnings ""; ""Abstract ""; ""1. Introduction""; ""2. Pharmacology""; ""2.1. Structure and Mechanisms of Action""; ""2.2. Absorption ""; ""2.3. Distribution ""; ""2.4. Metabolism and Excretion ""; ""2.5. Dosage and Administration ""; ""2.6. Pharmacogenomics"" ""2.7. Drug Interactions """"3. Clinical Uses ""; ""3.1. Autoimmune Conditions ""; ""a) Psoriatic Arthritis ""; ""b) Rheumatoid Arthritis ""; ""c) Ulcerative colitis (UC)""; ""d) Crohnâ€?s Disease (CD)""; ""e) Ankylosing Spondylitis""; ""f) Sarcoidosis""; ""g) BehÃet Disease""; ""h) Polychondritis""; ""i) Giant Cell Arteritis ""; ""j) SjÃ¶gren Syndrome ""; ""k) Juvenile Idiopathic Arthritis (JIA)""; ""l) Eosinophilic Fasciitis ""; ""3.2. Dermatological Conditions ""; ""A) Toxic Epidermic Necrolysis""; ""B) Subcorneal Pustular Dermatosis ""; ""C) Pyoderma Gangrenosum "" ""D) Chronic Eczema """"E) Hidradenitis Susppurativa (HS) ""; ""3.3. Other Verified Uses ""; ""a) SAPHO Syndrome ""; ""b) Kawasaki Disease ""; ""c) Pulmonary Fibrosis ""; ""d) Cap Polyposis ""; ""e) Postresuscitation Myocardial Dysfunction ""; ""f) B-Chronic Lymphocytic Leukemia ""; ""g) Diabetic Macular Edema ""; ""4. Warnings and Limitations""; ""4.1. Serious Infections ""; ""4.2. Malignancies ""; ""4.3. Hepatitis B virus Reactivation ""; ""4.4. Hepatotoxicity ""; ""4.5. Patients with Heart Failure ""; ""4.6. Hematological and Vascular Events ""; ""4.7. Hypersensitivity ""
Beschreibung:	xiv, 188 pages
ISBN:	1619423456 9781619423459 9781619423435 161942343X

Internformat

MARC


LEADER	00000nmm a2200000zc 4500
001	BV043961304
003	DE-604
005	00000000000000.0
007	cr\|uuu---uuuuu
008	161213s2012 \|\|\|\| o\|\|u\| \|\|\|\|\|\|eng d
020			\|a 1619423456 \|9 1-61942-345-6
020			\|a 9781619423459 \|9 978-1-61942-345-9
020			\|a 9781619423435 \|9 978-1-61942-343-5
020			\|a 161942343X \|9 1-61942-343-X
035			\|a (ZDB-4-EBA)ocn828140625
035			\|a (OCoLC)828140625
035			\|a (DE-599)BVBBV043961304
040			\|a DE-604 \|b ger \|e aacr
041	0		\|a eng
049			\|a DE-1047 \|a DE-1046
082	0		\|a 616.97/8061 \|2 23
245	1	0	\|a Infliximab \|b pharmacology, uses and limitations \|c Antonio D. Medrano Acevedo and Montserrat Fajardo Gaitan, editors
264		1	\|a New York \|b Nova Science Publishers \|c ©2012
300			\|a xiv, 188 pages
336			\|b txt \|2 rdacontent
337			\|b c \|2 rdamedia
338			\|b cr \|2 rdacarrier
490	0		\|a Immunology and immune system disorders
490	0		\|a Pharmacology-research, safety testing, and regulation series
500			\|a "Nova biomedical."
500			\|a Includes bibliographical references and index
500			\|a ""INFLIXIMAB PHARMACOLOGY, USES AND LIMITATIONS ""; ""INFLIXIMAB PHARMACOLOGY, USES AND LIMITATIONS ""; ""Contents ""; ""Preface ""; ""The Risk of Infection in Patients Treated with Infliximab ""; ""Abstract ""; ""1. Definition and Functions of Tumour Necrosis Factor ""; ""2. Anti-TNF Mechanism of Action: Infliximab ""; ""3. Risk of Infections in the Use of Infliximab: Evidence""; ""4. Risk of Infection from the Use of Anti-TNF (Inflximab): Mechanisms Involved""; ""5. Other Risk Factors for Infection in Patients Treated with Infliximab ""; ""6. Infections ""; ""Bacterial Infections""
500			\|a ""Listeria """"Tuberculosis ""; ""Virus ""; ""Fungal Infections ""; ""Histoplasmosis ""; ""Coccidioidomycosis ""; ""Cryptococcosis ""; ""Aspergillosis ""; ""Candidiasis""; ""Pneumocystosis ""; ""7. Special Situations""; ""Perisurgical Infections ""; ""Hepatitis B Virus Infection ""; ""Hepatitis C Virus Infection ""; ""HIV Infection ""; ""Vaccines ""; ""Conclusions ""; ""References ""; ""Infliximab in Inflammatory Bowel Disease ""; ""Abstract ""; ""Pharmacology""; ""Uses ""; ""Inflammatory Crohnâ€?s Disease ""; ""Fistulizing Crohnâ€?s Disease ""; ""Ulcerative Colitis""; ""Mucosal Healing ""
500			\|a ""Pouchitis""""Extraintestinal Manifestations ""; ""Limitations ""; ""Predictors of Response to Infliximab ""; ""Infections ""; ""Malignancies and Lymphoma ""; ""Cutaneous, Neurological and Liver Manifestations ""; ""Congestive Heart Failure ""; ""Pregnancy ""; ""References ""; ""Infliximab: Up-to-Date on Indications and Warnings ""; ""Abstract ""; ""1. Introduction""; ""2. Pharmacology""; ""2.1. Structure and Mechanisms of Action""; ""2.2. Absorption ""; ""2.3. Distribution ""; ""2.4. Metabolism and Excretion ""; ""2.5. Dosage and Administration ""; ""2.6. Pharmacogenomics""
500			\|a ""2.7. Drug Interactions """"3. Clinical Uses ""; ""3.1. Autoimmune Conditions ""; ""a) Psoriatic Arthritis ""; ""b) Rheumatoid Arthritis ""; ""c) Ulcerative colitis (UC)""; ""d) Crohnâ€?s Disease (CD)""; ""e) Ankylosing Spondylitis""; ""f) Sarcoidosis""; ""g) BehÃet Disease""; ""h) Polychondritis""; ""i) Giant Cell Arteritis ""; ""j) SjÃ¶gren Syndrome ""; ""k) Juvenile Idiopathic Arthritis (JIA)""; ""l) Eosinophilic Fasciitis ""; ""3.2. Dermatological Conditions ""; ""A) Toxic Epidermic Necrolysis""; ""B) Subcorneal Pustular Dermatosis ""; ""C) Pyoderma Gangrenosum ""
500			\|a ""D) Chronic Eczema """"E) Hidradenitis Susppurativa (HS) ""; ""3.3. Other Verified Uses ""; ""a) SAPHO Syndrome ""; ""b) Kawasaki Disease ""; ""c) Pulmonary Fibrosis ""; ""d) Cap Polyposis ""; ""e) Postresuscitation Myocardial Dysfunction ""; ""f) B-Chronic Lymphocytic Leukemia ""; ""g) Diabetic Macular Edema ""; ""4. Warnings and Limitations""; ""4.1. Serious Infections ""; ""4.2. Malignancies ""; ""4.3. Hepatitis B virus Reactivation ""; ""4.4. Hepatotoxicity ""; ""4.5. Patients with Heart Failure ""; ""4.6. Hematological and Vascular Events ""; ""4.7. Hypersensitivity ""
650		4	\|a Autoimmune Diseases / drug therapy
650		4	\|a Anti-inflammatory agents
650		4	\|a Infliximab / Therapeutic use
650		4	\|a Infliximab
650		7	\|a MEDICAL / Immunology \|2 bisacsh
650		7	\|a Autoimmune diseases / Chemotherapy \|2 fast
650		7	\|a Infliximab \|2 fast
650		4	\|a Medizin
650		4	\|a Infliximab
650		4	\|a Autoimmune diseases \|x Chemotherapy
700	1		\|a Medrano Acevedo, Antonio D. \|e Sonstige \|4 oth
700	1		\|a Fajardo Gaitan, Montserrat \|e Sonstige \|4 oth
912			\|a ZDB-4-EBA
999			\|a oai:aleph.bib-bvb.de:BVB01-029370009
966	e		\|u http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=540914 \|l FAW01 \|p ZDB-4-EBA \|q FAW_PDA_EBA \|x Aggregator \|3 Volltext
966	e		\|u http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=540914 \|l FAW02 \|p ZDB-4-EBA \|q FAW_PDA_EBA \|x Aggregator \|3 Volltext

Datensatz im Suchindex

_version_	1804176918949396480
any_adam_object
building	Verbundindex
bvnumber	BV043961304
collection	ZDB-4-EBA
ctrlnum	(ZDB-4-EBA)ocn828140625 (OCoLC)828140625 (DE-599)BVBBV043961304
dewey-full	616.97/8061
dewey-hundreds	600 - Technology (Applied sciences)
dewey-ones	616 - Diseases
dewey-raw	616.97/8061
dewey-search	616.97/8061
dewey-sort	3616.97 48061
dewey-tens	610 - Medicine and health
discipline	Medizin
format	Electronic eBook
fullrecord	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>05048nmm a2200589zc 4500</leader><controlfield tag="001">BV043961304</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">00000000000000.0</controlfield><controlfield tag="007">cr\|uuu---uuuuu</controlfield><controlfield tag="008">161213s2012 \|\|\|\| o\|\|u\| \|\|\|\|\|\|eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">1619423456</subfield><subfield code="9">1-61942-345-6</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9781619423459</subfield><subfield code="9">978-1-61942-345-9</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9781619423435</subfield><subfield code="9">978-1-61942-343-5</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">161942343X</subfield><subfield code="9">1-61942-343-X</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ZDB-4-EBA)ocn828140625</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)828140625</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV043961304</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">aacr</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-1047</subfield><subfield code="a">DE-1046</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">616.97/8061</subfield><subfield code="2">23</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Infliximab</subfield><subfield code="b">pharmacology, uses and limitations</subfield><subfield code="c">Antonio D. Medrano Acevedo and Montserrat Fajardo Gaitan, editors</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">New York</subfield><subfield code="b">Nova Science Publishers</subfield><subfield code="c">©2012</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">xiv, 188 pages</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="0" ind2=" "><subfield code="a">Immunology and immune system disorders</subfield></datafield><datafield tag="490" ind1="0" ind2=" "><subfield code="a">Pharmacology-research, safety testing, and regulation series</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">"Nova biomedical."</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">Includes bibliographical references and index</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">""INFLIXIMAB PHARMACOLOGY, USES AND LIMITATIONS ""; ""INFLIXIMAB PHARMACOLOGY, USES AND LIMITATIONS ""; ""Contents ""; ""Preface ""; ""The Risk of Infection in Patients Treated with Infliximab ""; ""Abstract ""; ""1. Definition and Functions of Tumour Necrosis Factor ""; ""2. Anti-TNF Mechanism of Action: Infliximab ""; ""3. Risk of Infections in the Use of Infliximab: Evidence""; ""4. Risk of Infection from the Use of Anti-TNF (Inflximab): Mechanisms Involved""; ""5. Other Risk Factors for Infection in Patients Treated with Infliximab ""; ""6. Infections ""; ""Bacterial Infections""</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">""Listeria """"Tuberculosis ""; ""Virus ""; ""Fungal Infections ""; ""Histoplasmosis ""; ""Coccidioidomycosis ""; ""Cryptococcosis ""; ""Aspergillosis ""; ""Candidiasis""; ""Pneumocystosis ""; ""7. Special Situations""; ""Perisurgical Infections ""; ""Hepatitis B Virus Infection ""; ""Hepatitis C Virus Infection ""; ""HIV Infection ""; ""Vaccines ""; ""Conclusions ""; ""References ""; ""Infliximab in Inflammatory Bowel Disease ""; ""Abstract ""; ""Pharmacology""; ""Uses ""; ""Inflammatory Crohnâ€?s Disease ""; ""Fistulizing Crohnâ€?s Disease ""; ""Ulcerative Colitis""; ""Mucosal Healing ""</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">""Pouchitis""""Extraintestinal Manifestations ""; ""Limitations ""; ""Predictors of Response to Infliximab ""; ""Infections ""; ""Malignancies and Lymphoma ""; ""Cutaneous, Neurological and Liver Manifestations ""; ""Congestive Heart Failure ""; ""Pregnancy ""; ""References ""; ""Infliximab: Up-to-Date on Indications and Warnings ""; ""Abstract ""; ""1. Introduction""; ""2. Pharmacology""; ""2.1. Structure and Mechanisms of Action""; ""2.2. Absorption ""; ""2.3. Distribution ""; ""2.4. Metabolism and Excretion ""; ""2.5. Dosage and Administration ""; ""2.6. Pharmacogenomics""</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">""2.7. Drug Interactions """"3. Clinical Uses ""; ""3.1. Autoimmune Conditions ""; ""a) Psoriatic Arthritis ""; ""b) Rheumatoid Arthritis ""; ""c) Ulcerative colitis (UC)""; ""d) Crohnâ€?s Disease (CD)""; ""e) Ankylosing Spondylitis""; ""f) Sarcoidosis""; ""g) BehÃet Disease""; ""h) Polychondritis""; ""i) Giant Cell Arteritis ""; ""j) SjÃ¶gren Syndrome ""; ""k) Juvenile Idiopathic Arthritis (JIA)""; ""l) Eosinophilic Fasciitis ""; ""3.2. Dermatological Conditions ""; ""A) Toxic Epidermic Necrolysis""; ""B) Subcorneal Pustular Dermatosis ""; ""C) Pyoderma Gangrenosum ""</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">""D) Chronic Eczema """"E) Hidradenitis Susppurativa (HS) ""; ""3.3. Other Verified Uses ""; ""a) SAPHO Syndrome ""; ""b) Kawasaki Disease ""; ""c) Pulmonary Fibrosis ""; ""d) Cap Polyposis ""; ""e) Postresuscitation Myocardial Dysfunction ""; ""f) B-Chronic Lymphocytic Leukemia ""; ""g) Diabetic Macular Edema ""; ""4. Warnings and Limitations""; ""4.1. Serious Infections ""; ""4.2. Malignancies ""; ""4.3. Hepatitis B virus Reactivation ""; ""4.4. Hepatotoxicity ""; ""4.5. Patients with Heart Failure ""; ""4.6. Hematological and Vascular Events ""; ""4.7. Hypersensitivity ""</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Autoimmune Diseases / drug therapy</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Anti-inflammatory agents</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Infliximab / Therapeutic use</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Infliximab</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">MEDICAL / Immunology</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Autoimmune diseases / Chemotherapy</subfield><subfield code="2">fast</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Infliximab</subfield><subfield code="2">fast</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Medizin</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Infliximab</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Autoimmune diseases</subfield><subfield code="x">Chemotherapy</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Medrano Acevedo, Antonio D.</subfield><subfield code="e">Sonstige</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Fajardo Gaitan, Montserrat</subfield><subfield code="e">Sonstige</subfield><subfield code="4">oth</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-4-EBA</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-029370009</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=540914</subfield><subfield code="l">FAW01</subfield><subfield code="p">ZDB-4-EBA</subfield><subfield code="q">FAW_PDA_EBA</subfield><subfield code="x">Aggregator</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=540914</subfield><subfield code="l">FAW02</subfield><subfield code="p">ZDB-4-EBA</subfield><subfield code="q">FAW_PDA_EBA</subfield><subfield code="x">Aggregator</subfield><subfield code="3">Volltext</subfield></datafield></record></collection>
id	DE-604.BV043961304
illustrated	Not Illustrated
indexdate	2024-07-10T07:39:49Z
institution	BVB
isbn	1619423456 9781619423459 9781619423435 161942343X
language	English
oai_aleph_id	oai:aleph.bib-bvb.de:BVB01-029370009
oclc_num	828140625
open_access_boolean
owner	DE-1047 DE-1046
owner_facet	DE-1047 DE-1046
physical	xiv, 188 pages
psigel	ZDB-4-EBA ZDB-4-EBA FAW_PDA_EBA
publishDate	2012
publishDateSearch	2012
publishDateSort	2012
publisher	Nova Science Publishers
record_format	marc
series2	Immunology and immune system disorders Pharmacology-research, safety testing, and regulation series
spelling	Infliximab pharmacology, uses and limitations Antonio D. Medrano Acevedo and Montserrat Fajardo Gaitan, editors New York Nova Science Publishers ©2012 xiv, 188 pages txt rdacontent c rdamedia cr rdacarrier Immunology and immune system disorders Pharmacology-research, safety testing, and regulation series "Nova biomedical." Includes bibliographical references and index ""INFLIXIMAB PHARMACOLOGY, USES AND LIMITATIONS ""; ""INFLIXIMAB PHARMACOLOGY, USES AND LIMITATIONS ""; ""Contents ""; ""Preface ""; ""The Risk of Infection in Patients Treated with Infliximab ""; ""Abstract ""; ""1. Definition and Functions of Tumour Necrosis Factor ""; ""2. Anti-TNF Mechanism of Action: Infliximab ""; ""3. Risk of Infections in the Use of Infliximab: Evidence""; ""4. Risk of Infection from the Use of Anti-TNF (Inflximab): Mechanisms Involved""; ""5. Other Risk Factors for Infection in Patients Treated with Infliximab ""; ""6. Infections ""; ""Bacterial Infections"" ""Listeria """"Tuberculosis ""; ""Virus ""; ""Fungal Infections ""; ""Histoplasmosis ""; ""Coccidioidomycosis ""; ""Cryptococcosis ""; ""Aspergillosis ""; ""Candidiasis""; ""Pneumocystosis ""; ""7. Special Situations""; ""Perisurgical Infections ""; ""Hepatitis B Virus Infection ""; ""Hepatitis C Virus Infection ""; ""HIV Infection ""; ""Vaccines ""; ""Conclusions ""; ""References ""; ""Infliximab in Inflammatory Bowel Disease ""; ""Abstract ""; ""Pharmacology""; ""Uses ""; ""Inflammatory Crohnâ€?s Disease ""; ""Fistulizing Crohnâ€?s Disease ""; ""Ulcerative Colitis""; ""Mucosal Healing "" ""Pouchitis""""Extraintestinal Manifestations ""; ""Limitations ""; ""Predictors of Response to Infliximab ""; ""Infections ""; ""Malignancies and Lymphoma ""; ""Cutaneous, Neurological and Liver Manifestations ""; ""Congestive Heart Failure ""; ""Pregnancy ""; ""References ""; ""Infliximab: Up-to-Date on Indications and Warnings ""; ""Abstract ""; ""1. Introduction""; ""2. Pharmacology""; ""2.1. Structure and Mechanisms of Action""; ""2.2. Absorption ""; ""2.3. Distribution ""; ""2.4. Metabolism and Excretion ""; ""2.5. Dosage and Administration ""; ""2.6. Pharmacogenomics"" ""2.7. Drug Interactions """"3. Clinical Uses ""; ""3.1. Autoimmune Conditions ""; ""a) Psoriatic Arthritis ""; ""b) Rheumatoid Arthritis ""; ""c) Ulcerative colitis (UC)""; ""d) Crohnâ€?s Disease (CD)""; ""e) Ankylosing Spondylitis""; ""f) Sarcoidosis""; ""g) BehÃet Disease""; ""h) Polychondritis""; ""i) Giant Cell Arteritis ""; ""j) SjÃ¶gren Syndrome ""; ""k) Juvenile Idiopathic Arthritis (JIA)""; ""l) Eosinophilic Fasciitis ""; ""3.2. Dermatological Conditions ""; ""A) Toxic Epidermic Necrolysis""; ""B) Subcorneal Pustular Dermatosis ""; ""C) Pyoderma Gangrenosum "" ""D) Chronic Eczema """"E) Hidradenitis Susppurativa (HS) ""; ""3.3. Other Verified Uses ""; ""a) SAPHO Syndrome ""; ""b) Kawasaki Disease ""; ""c) Pulmonary Fibrosis ""; ""d) Cap Polyposis ""; ""e) Postresuscitation Myocardial Dysfunction ""; ""f) B-Chronic Lymphocytic Leukemia ""; ""g) Diabetic Macular Edema ""; ""4. Warnings and Limitations""; ""4.1. Serious Infections ""; ""4.2. Malignancies ""; ""4.3. Hepatitis B virus Reactivation ""; ""4.4. Hepatotoxicity ""; ""4.5. Patients with Heart Failure ""; ""4.6. Hematological and Vascular Events ""; ""4.7. Hypersensitivity "" Autoimmune Diseases / drug therapy Anti-inflammatory agents Infliximab / Therapeutic use Infliximab MEDICAL / Immunology bisacsh Autoimmune diseases / Chemotherapy fast Infliximab fast Medizin Autoimmune diseases Chemotherapy Medrano Acevedo, Antonio D. Sonstige oth Fajardo Gaitan, Montserrat Sonstige oth
spellingShingle	Infliximab pharmacology, uses and limitations Autoimmune Diseases / drug therapy Anti-inflammatory agents Infliximab / Therapeutic use Infliximab MEDICAL / Immunology bisacsh Autoimmune diseases / Chemotherapy fast Infliximab fast Medizin Autoimmune diseases Chemotherapy
title	Infliximab pharmacology, uses and limitations
title_auth	Infliximab pharmacology, uses and limitations
title_exact_search	Infliximab pharmacology, uses and limitations
title_full	Infliximab pharmacology, uses and limitations Antonio D. Medrano Acevedo and Montserrat Fajardo Gaitan, editors
title_fullStr	Infliximab pharmacology, uses and limitations Antonio D. Medrano Acevedo and Montserrat Fajardo Gaitan, editors
title_full_unstemmed	Infliximab pharmacology, uses and limitations Antonio D. Medrano Acevedo and Montserrat Fajardo Gaitan, editors
title_short	Infliximab
title_sort	infliximab pharmacology uses and limitations
title_sub	pharmacology, uses and limitations
topic	Autoimmune Diseases / drug therapy Anti-inflammatory agents Infliximab / Therapeutic use Infliximab MEDICAL / Immunology bisacsh Autoimmune diseases / Chemotherapy fast Infliximab fast Medizin Autoimmune diseases Chemotherapy
topic_facet	Autoimmune Diseases / drug therapy Anti-inflammatory agents Infliximab / Therapeutic use Infliximab MEDICAL / Immunology Autoimmune diseases / Chemotherapy Medizin Autoimmune diseases Chemotherapy
work_keys_str_mv	AT medranoacevedoantoniod infliximabpharmacologyusesandlimitations AT fajardogaitanmontserrat infliximabpharmacologyusesandlimitations

Verfügbarkeit

Es ist kein Print-Exemplar vorhanden.

Fernleihe Bestellen Achtung: Nicht im THWS-Bestand!

MARC

Datensatz im Suchindex

Es ist kein Print-Exemplar vorhanden.

Ähnliche Einträge